Highlights • When reassessed, most cancer drugs did not exhibit substantial benefit. • Over a third of drug trials changed benefit classification at 3-year reassessment. • However, a nearly equal number of trials increased and decreased their benefit. • Thus, it may be useful to regularly reassess the benefit of approved cancer drugs. Abstract Background Increasingly, cancer drugs are being approved based on surrogate measurements of efficacy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile